• Clario accelerates your clinical trial from initiation to implementation. LEARN MORE →

Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)

      Discover Clario's AI solutions, where innovation meets expertise. Since 2018, we have revolutionized clinical trial endpoint analyses with more than 30 AI-enabled solutions across 600+ active trials, enhancing data quality and patient privacy while expediting data collection processes.

      Go to page
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion for Clinical Trials
      • Precision Motion for Clinical Trials
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, etc.)
      • Home & Hybrid DCT Spirometry​
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials

      All the precision endpoint technology and services your virtual or hybrid trial needs to deliver more certain outcomes.

      Go to page
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology Clinical Trials
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Security Governance
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Solutions
    • eCOA Clinical Trials
      • eCOA Clinical Trials
      • eCOA Live
      • eCOA Multimedia
      • eCOA Rater and Participant Training
      • eCOA Rescue Studies
      • Suicidal Ideation
    • Artificial Intelligence (AI)
    • Cardiac Safety
      • Cardiac Safety
      • Arrhythmia Analysis
      • Blood Pressure Services
      • ECG — On-site to DCT and Phase I-IV
      • Phase I/TQT Cardiac Assessment
      • Regulatory Consultation and Statistical Analysis Expertise
    • Medical Imaging
      • Medical Imaging
      • Medical Imaging science team
      • Image Redact AI
      • Image Repository
      • Imaging Platform
      • Image Workflow
      • Modalities
      • SMART Submit
    • Precision Motion for Clinical Trials
      • Precision Motion for Clinical Trials
      • Precision Motion: Scientific Consulting Services
      • Precision Motion: Scientific Publications
    • Respiratory Solutions
      • Respiratory Solutions
      • Site-Based Spirometry (FEV1, FVC, PEF, etc.)
      • Home & Hybrid DCT Spirometry​
      • Cough and Lung Sounds
      • Diffusing Capacity (DLCO)
    • Trial Enablement
      • Trial Enablement
      • Clinical Adjudication
      • Eligibility Solution
      • Reporting & Analytics
      • Source Document Manager
    • Decentralized Trials
      • Decentralized Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
    • Oncology Clinical Trials
    • Ophthalmology
    • Respiratory Solutions
  • Resources
    • Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Security Governance
    • Strategic Partnerships
    • Values & Culture
  • Support
    • Customer Support
    • In-Country Cardiac Safety Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home About Newsroom Clario’s Otis Johnson, Ph.D., honored as impact leader finalist by Informa’s Biotech Week Boston Awards

Clario’s Otis Johnson, Ph.D., honored as impact leader finalist by Informa’s Biotech Week Boston Awards

Chief Diversity, Inclusion, and Sustainability Officer recognized for their environmentally-conscious efforts towards sustainability and good governance 

PHILADELPHIA, PA – October 6, 2022 –, Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, announced that Otis Johnson, Ph.D., Chief Diversity, Inclusion, and Sustainability Officer, has been recognized as a finalist for the Impact Leader Award at Informa’s Biotech Week Boston (BWB) Awards. The BWB Impact Leader award is in recognition of environmentally conscious efforts toward sustainability and good governance.

“We do not believe enough is being done to measure and reduce the carbon footprint of the clinical trial industry, so we have stepped up to measure and reduce our environmental impact. We are firm in the knowledge that healthy patients can only thrive on a healthy planet.“

“The BWB Impact Leader award recognition comes because of strong contributions from all Clario’s people, from our interns through to the CEO. We needed accurate data from suppliers and thousands of employees to understand the true impact of our global operations. Collaboration, transparency and accuracy are key enablers for Clario,” said Dr. Johnson.

Within a year, highly engaged employees made it possible for the organization to: 

  • Robustly measure its carbon footprint and identify targeted areas for emission reductions 
  • Reduce its global office footprint 
  • Switch its largest facility to 100% green energy 
  • Redesign products and packaging for efficiency and reduced environmental impact 
  • Adjust its service delivery models and logistics 
  • Create new value out of retired devices and technology through donations

“Through our own operations, we have the power to reduce health disparities and do so while positively impacting the planet. Clario’s go-forward strategy on our journey to net-zero is data driven and grounded in science. We aspire to be good corporate citizens to both people and planet”, said Dr. Johnson. 

Dr. Johnson was recently named to the prestigious Pharmavoice100 list of most inspiring life-science industry leaders, and named a Mogul Top 100 Diversity, Equity and Inclusion (DEI) leader for his significant contributions to increasing the diversity of clinical trial participants and throughout the clinical trial workforce. He applied the same winning DEI approach to his environmental strategy, going after the data and actionable business insights, to form a multiyear strategy with specific and measurable environmental goals.

The BWB Awards recognize individuals and organizations who have made positive and innovative contributions to the life sciences industry. Finalists were recognized and winners were announced at a ceremony in Boston, MA on September 27. 

Learn more about Clario’s environmental, social, and governance (ESG) work.

Clario_Brochure_ESG_050622

About Clario

Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario’s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years. 

For more information, go to Clario.com or follow us on LinkedIn and Twitter. 

Clario Media Contact 
Duncan Cantor
Snr. Director, Content and Communications 
[email protected]
+44 7307 533 162 

Back to news
Share
Twitter Facebook LinkedIn

Latest News

See all news

Clario Reveals Updated Oncology Trial Solutions Portfolio: The Industry’s Widest Range of Endpoint Collection Technologies

September 1, 2023 Read more

Dr. Vince Clinical Research, Clario Form Strategic Partnership to Deliver Innovative Cardiac Assessments in Clinical Trials

August 29, 2023 Read more

A checklist for unlocking the promise of AI in clinical trials

August 22, 2023 Read more
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

Thanks for your form. Our team will be in touch very soon.

  • © 2023 Clario

    • Legal and Privacy Terms
    • Security Governance
    • Cookie Policy
    • Impressum

Please enter your business email before proceeding to xTalks to complete registration.

×